论文部分内容阅读
目的:评价整肠生、思密达联合治疗婴幼儿急性腹泻的临床疗效和安全性。方法:将80例腹泻婴幼儿随机分为治疗组和对照组,每组40例。对照组:应用抗感染、抗病毒及补液等对症治疗。治疗组:在对照组的基础上加用整肠生:<1岁,0.0625/次,3次/日;1～3岁,0.125/次,2次/日,口服。思密达:<1岁,1.0g/次,3次/日;1～3岁,1.5g/日,3次/日。结果:治疗组总有效率为92.5%,显效率为40%,两者差异显著(p<0.01),无明显毒副作用。结论:整肠生、思密达联合治疗婴幼儿急性腹泻是有效而安全的。
Objective: To evaluate the clinical efficacy and safety of the treatment of acute diarrhea in children and adolescents with the combination of intestine and Smecta. Methods: 80 cases of diarrhea infants and young children were randomly divided into treatment group and control group, 40 cases in each group. Control group: application of anti-infection, anti-virus and rehydration symptomatic treatment. Treatment group: on the basis of the control group plus intestinal consolidation: <1 year old, 0.0625 / time, 3 times / day; 1 to 3 years old, 0.125 / time, 2 times / day, orally. Smectite: <1 year old, 1.0g / time, 3 times / day; 1 to 3 years old, 1.5g / day, 3 times / day. Results: The total effective rate was 92.5% in the treatment group, the effective rate was 40%, the difference was significant (p <0.01), no obvious side effects. Conclusion: The treatment of acute intestinal diarrhea and smecta in the treatment of acute diarrhea in infants and children is effective and safe.